From the American Academy of Ophthalmology

The U.S. Food and Drug Administration has approved Lucentis (ranibizumab injection) for the treatment of diabetic macular edema. The drug’s safety and effectiveness to treat DME were established in two clinical studies that showed a 34 to 45 percent improvement in patients treated monthly with 0.3 mg of Lucentis over a two-year period. Ophthalmologists should check with their Medicare carriers to determine coverage for Lucentis to treat DME.